Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	115.77	132.19	151.02	149.16	152.11	29.25
Cash & Short-Term Investments	115.77	132.19	151.02	149.16	152.11	29.25
Cash Growth	-16.94%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Other Receivables	0.67	2.45	2.71	3.19	9.14	4.85
Receivables	0.67	2.45	2.71	3.19	9.14	4.85
Prepaid Expenses	0.7	0.93	0.65	0.35	0.37	0.44
Total Current Assets	117.14	135.57	154.39	152.71	161.62	34.54
Total Assets	117.14	135.57	154.39	152.71	161.62	34.54
Accounts Payable	7	9.63	4.32	3.83	4.74	3.99
Accrued Expenses	9.56	4.84	7.3	5.95	5.61	3.32
Current Unearned Revenue	0.83	0.84	0.92	0.44	0.44	-
Total Current Liabilities	17.38	15.3	12.53	10.21	10.8	7.31
Total Liabilities	17.38	15.3	12.53	10.21	10.8	7.31
Common Stock	0.09	0.09	0.08	0.08	0.08	0.06
Additional Paid-In Capital	459.05	456.25	434.84	387.98	348.33	186.85
Retained Earnings	-359.38	-336.07	-293.07	-245.56	-197.59	-159.68
Shareholders' Equity	99.76	120.26	141.85	142.49	150.82	27.24
Total Liabilities & Equity	117.14	135.57	154.39	152.71	161.62	34.54
Net Cash (Debt)	115.77	132.19	151.02	149.16	152.11	29.25
Net Cash Growth	-16.94%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Net Cash Per Share	1.37	1.58	1.89	1.94	2.18	0.50
Filing Date Shares Outstanding	85.37	84.82	82.09	77.96	76.02	66.96
Total Common Shares Outstanding	85.33	84.8	82.07	77.94	75.92	62.05
Working Capital	99.76	120.26	141.85	142.49	150.82	27.24
Book Value Per Share	1.17	1.42	1.73	1.83	1.99	0.44
Tangible Book Value	99.76	120.26	141.85	142.49	150.82	27.24
Tangible Book Value Per Share	1.17	1.42	1.73	1.83	1.99	0.44

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q